trabedersen

Nucleic acidexperimental

Clinical trial activity

8 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
6
Phase 3
3
Phase 4
0

Earliest trial started Apr 1, 2003 (NCT00431561)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2005

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2008

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ap 12009
  • ap 12009
  • ap-2-09
  • trabedersen
  • trabedersen
  • trabedersen

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06079346Phase 2/Phase 3 (Phase 3)May 1, 2024Oncotelic Inc.
NCT05935774Phase 2Dec 1, 2023Genentech, University of Washington
NCT05425576Phase 2Dec 1, 2022Oncotelic Inc.
NCT04801017Phase 2Apr 30, 2021Oncotelic Inc.
NCT04770610Phase 3Apr 1, 2021Ocumension (Hong Kong) Limited, ORA, Inc., Statistics & Data Corporation
NCT00761280Phase 3Dec 1, 2008Isarna Therapeutics GmbH, University of Montreal
NCT00844064Phase 1Jan 1, 2005Isarna Therapeutics GmbH
NCT00431561Phase 2Apr 1, 2003Isarna Therapeutics GmbH, University of Regensburg
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Isarna Therapeutics GmbHFor profit3332003
Oncotelic Inc.For profit3322021
GenentechFor profit1012023
Ocumension (Hong Kong) LimitedFor profit1112021
ORA, Inc.For profit1012021
Statistics & Data CorporationFor profit1012021
University of MontrealAcademic/Hospital1012008
University of RegensburgAcademic/Hospital1012003
University of WashingtonAcademic/Hospital1112023
9 organizations
Page 1 / 1